Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Express Scripts
Federal Trade Commission
Medtronic
AstraZeneca
Cantor Fitzgerald
Argus Health
Deloitte
Daiichi Sankyo
McKinsey

Generated: October 23, 2017

DrugPatentWatch Database Preview

Valeant Luxembourg Company Profile

« Back to Dashboard

What is the competitive landscape for VALEANT LUXEMBOURG, and what generic alternatives to VALEANT LUXEMBOURG drugs are available?

VALEANT LUXEMBOURG has six approved drugs.

There is one US patent protecting VALEANT LUXEMBOURG drugs.

There are fifty-two patent family members on VALEANT LUXEMBOURG drugs in seventeen countries and nine supplementary protection certificates in seven countries.

Summary for Applicant: Valeant Luxembourg

International Patents:52
US Patents:1
Tradenames:4
Ingredients:5
NDAs:6
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Luxembourg
GRIFULVIN V
griseofulvin, microsize
TABLET;ORAL062279-003Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Luxembourg
TARGRETIN
bexarotene
CAPSULE;ORAL021055-001Dec 29, 1999ABRXYesYes► Subscribe► Subscribe► Subscribe
Valeant Luxembourg
GRIFULVIN V
griseofulvin, microsize
SUSPENSION;ORAL062483-001Jan 26, 1984DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Luxembourg
GRIFULVIN V
griseofulvin, microcrystalline
TABLET;ORAL062279-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Luxembourg
TARGRETIN
bexarotene
GEL;TOPICAL021056-001Jun 28, 2000RXYesYes► Subscribe► Subscribe ► Subscribe
Valeant Luxembourg
TARGRETIN
bexarotene
CAPSULE;ORAL021055-001Dec 29, 1999ABRXYesYes► Subscribe► Subscribe ► Subscribe
Valeant Luxembourg
GRIFULVIN V
griseofulvin, microcrystalline
TABLET;ORAL062279-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Luxembourg
ERTACZO
sertaconazole nitrate
CREAM;TOPICAL021385-001Dec 10, 2003RXYesYes► Subscribe► Subscribe► Subscribe
Valeant Luxembourg
VISUDYNE
verteporfin
INJECTABLE;INJECTION021119-001Apr 12, 2000RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Valeant Luxembourg

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Luxembourg
ERTACZO
sertaconazole nitrate
CREAM;TOPICAL021385-001Dec 10, 2003► Subscribe► Subscribe
Valeant Luxembourg
TARGRETIN
bexarotene
CAPSULE;ORAL021055-001Dec 29, 1999► Subscribe► Subscribe
Valeant Luxembourg
TARGRETIN
bexarotene
GEL;TOPICAL021056-001Jun 28, 2000► Subscribe► Subscribe
Valeant Luxembourg
VISUDYNE
verteporfin
INJECTABLE;INJECTION021119-001Apr 12, 2000► Subscribe► Subscribe
Valeant Luxembourg
TARGRETIN
bexarotene
GEL;TOPICAL021056-001Jun 28, 2000► Subscribe► Subscribe
Valeant Luxembourg
VISUDYNE
verteporfin
INJECTABLE;INJECTION021119-001Apr 12, 2000► Subscribe► Subscribe
Valeant Luxembourg
TARGRETIN
bexarotene
GEL;TOPICAL021056-001Jun 28, 2000► Subscribe► Subscribe
Valeant Luxembourg
TARGRETIN
bexarotene
GEL;TOPICAL021056-001Jun 28, 2000► Subscribe► Subscribe
Valeant Luxembourg
TARGRETIN
bexarotene
CAPSULE;ORAL021055-001Dec 29, 1999► Subscribe► Subscribe
Valeant Luxembourg
TARGRETIN
bexarotene
CAPSULE;ORAL021055-001Dec 29, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for VALEANT LUXEMBOURG drugs

Drugname Dosage Strength Tradename Submissiondate
bexarotene
Capsules75 mg
TARGRETIN
6/6/2011

Non-Orange Book Patents for Valeant Luxembourg

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,780,676 Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors► Subscribe
7,655,699Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors► Subscribe
6,320,074 Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors► Subscribe
6,043,279 Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors► Subscribe
6,610,883 Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Valeant Luxembourg Drugs

Country Document Number Estimated Expiration
Germany69329278► Subscribe
Australia5586894► Subscribe
Austria195716► Subscribe
World Intellectual Property Organization (WIPO)9321146► Subscribe
World Intellectual Property Organization (WIPO)9415901► Subscribe
European Patent Office0678087► Subscribe
World Intellectual Property Organization (WIPO)9504036► Subscribe
JapanH08511027► Subscribe
Germany69324043► Subscribe
Spain2139063► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Valeant Luxembourg Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00037Netherlands► SubscribePRODUCT NAME: VERTEPORFINE, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/00/140/001 20000727
2001 00032Denmark► Subscribe
01C/010Belgium► SubscribePRODUCT NAME: VERTEPORFIN; NAT. REGISTRATION NO./DATE: EU/1/00/140/001 20000727; FIRST REGISTRATION: CH 55269 19991215
C/GB01/041United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB01/041 GRANTED TO EISAI R + D MANAGEMENT., LTD. IN RESPECT OF THE PRODUCT BEXAROTENE (4-(1-(3, 5, 5, 8, 8-PENTAMETHYL-5, 6, 7, 8-TETRAHYDRO-2-NAPHTHALENYL)VINYL)BENZOIC ACID), WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 6469 DATED 15/05/2013 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 01/04/2016.
00054Netherlands► SubscribePRODUCT NAME: BEXAROTENE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF IN DE VORM VAN EEN ESTER MET EEN HYDROXYVER- BINDING MET DE FORMULE R9OH, WAARIN R9 EEN; NAT. REGISTRATION NO/DATE: EU/1/01/178/001 20010329; FIRST REGISTRATION: EU/1/01/178/001 20010329
C013/2001Ireland► SubscribeSPC013/2001: 20031205, EXPIRES: 20160328
C/GB01/005United Kingdom► SubscribePRODUCT NAME: VERTEPORFIN OPTIONALLY IN THE FORM OF A SALT THEREOF; REGISTERED: UK EU/1/00/140/001 20000727
2001Austria► SubscribePRODUCT NAME: VERTEPORFIN; REGISTRATION NO/DATE: EU/1/00/140/001 20000727
C0027France► SubscribePRODUCT NAME: BEXAROTENE; REGISTRATION NO/DATE: EU/1/01/178/001 20010329
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Argus Health
Teva
US Army
Fish and Richardson
Deloitte
Daiichi Sankyo
Accenture
Cantor Fitzgerald
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot